Sanofi US Services Inc. proposed new production activities at its facility in Ridgefield, New Jersey, and submitted a notification to the Foreign-Trade Zones (FTZ) Board on December 18, 2024. This notification was reviewed according to the Board's regulations, and a public comment invitation was published in the Federal Register on January 6, 2025. By April 17, 2025, the Board decided that no further review was needed, and authorized the activity under the FTZ Act and regulations. The decision was communicated to Sanofi with a formal notice from the Executive Secretary, Elizabeth Whiteman.
Simple Explanation
Sanofi, a medicine company, got permission to start making new medicines in New Jersey. Some people had the chance to say what they thought about this idea and nobody said it needed more checking, so it was approved quickly.